Small Business Innovation Research · Small Business Technology Transfer
VIVA Viral Vaccines, Inc: SBIR & STTR awards
1 awards worth $300.0K to 1 companies since 2025 match these filters. Phase I tests an idea (usually a few hundred thousand dollars); Phase II builds it (often $1M or more).
VIVA Viral Vaccines, Inc's federal contracts and grants · All SBIR & STTR awards
Awards by year
| Year | Phase I | Phase II | Amount |
|---|---|---|---|
| 2025 | 1 | 0 | $300.0K |
The latest year fills in over months: agencies report awards to SBIR.gov with a lag.
Latest matching awards
| Award | Company | Agency | Phase | Amount | Date |
|---|---|---|---|---|---|
| Broad-spectrum, multivalent platform for pan-influenza vaccine · topic NIAID | VIVA Viral Vaccines, Inc · New York | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $300.0K | 2025-09-25 |
Source: SBIR.gov award data (SBA) ↗, awards through 2026-08-28. Amounts are as agencies report them to SBA. SBIR/STTR contracts also appear in USAspending as ordinary awards; grants (NIH, NSF, DOE) appear as assistance. Open topics are posted by each agency; see Opportunities for contract notices.